Warning: Declaration of Suffusion_MM_Walker::start_el($output, $item, $depth, $args) should be compatible with Walker_Nav_Menu::start_el(&$output, $item, $depth = 0, $args = NULL, $id = 0) in /home/hygiol5/public_html/wp-content/themes/suffusion/library/suffusion-walkers.php on line 39
May 142013

The Hygiology Post ®  is presenting information about a company that seems to have much potential to help many people. Both 2012 and 2013 appear to be pivotal years in determining how helpful the patented technologies may actually be for people. Senesco Technologies has continued to update information on its web site (https://www.senesco.com/; retrieved on 05-14-13). As a matter of disclosure : The author continues to be a current shareholder in the company.

The following article titled “Senesco Announces Presentation on Combination Therapy with Novel Nanoparticle, SNS01-T, and Bortezomib Results in Synergistic Cytotoxicity In Vitro and In Vivo in Multiple Myeloma Poster Presentation at 16th Annual Meeting of American Society of Gene & C” retrieved on 5-6-13) was apparently released earlier this morning on the company web site (www.senesco.com/; retrieved on 5-14-2013) and began in the following way (www.senesco.com/newsitem.php?id=278; retrieved on 5-14-2013) :

“BRIDGEWATER, N.J. (May 14th, 2013) – Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTC QB: SNTI), announced today that a poster presentation will be delivered at the 16th Annual Meeting of the American Society of Gene & Cell Therapy. The conference will be held May 15-18th, 2013 at the Salt Palace Convention Center in Salt Lake City, Utah. The Company will present during the Cancer-Targeted Gene & Cell Therapy: Viral Vector / siRNA-Mediated Therapies Session, which will begin Thursday, May 16, at 4:00 p.m. The poster presentation, entitled “Combination Therapy with Novel Nanoparticle, SNS01-T, and Bortezomib Results in Synergistic Cytotoxicity In Vitro and In Vivo in Multiple Myeloma”, will be delivered by Catherine Taylor, who is from Senesco CSO John Thompson’s research laboratory at the University of Waterloo in Ontario, Canada.

About SNS01-T

SNS01-T is a novel approach to cancer therapy that is designed to selectively trigger apoptosis in B-cell cancers such as multiple myeloma, and, mantle cell and diffuse large B-cell lymphomas. Senesco is the sponsor of the Phase 1b/2a study that is actively enrolling patients at Mayo Clinic in Rochester, MN, the University of Arkansas for Medical Sciences in Little Rock, the Mary Babb Randolph Cancer Center in Morgantown, WV, and the John Theurer Cancer Center at Hackensack University Medical Center in Hackensack, NJ. https://www.clinicaltrials.gov/ct2/show/NCT01435720?term=SNS01-T&rank=1”


The Hygiology Post ® welcomes feedback from readers as to whether the articles (individually and/or collectively) help fulfill its vision and mission.


Louis DeCola, Jr.                                    © 2013 The Hygiology Post ®